Get the Stockscreener App
33.80
9.21%
2.85
After Hours:
33.50
-0.30
-0.89%
Moderna Inc stock is traded at $33.80, with a volume of 23.45M.
It is up +9.21% in the last 24 hours and up +39.78% over the past month.
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 35 mRNA development candidates in clinical studies as of August 2025. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.
See More
Previous Close:
$30.95
Open:
$31.28
24h Volume:
23.45M
Relative Volume:
2.16
Market Cap:
$13.21B
Revenue:
$3.14B
Net Income/Loss:
$-3.36B
P/E Ratio:
-3.8717
EPS:
-8.73
Net Cash Flow:
$-4.03B
1W Performance:
+14.73%
1M Performance:
+39.78%
6M Performance:
+33.07%
1Y Performance:
-14.56%
1-Day Range:
$31.17
$34.25
1-Week Range:
$28.66
$34.25
52-Week Range:
$22.28
$48.92
Moderna Inc Stock (MRNA) Company Profile
Name
Moderna Inc
Sector
Industry
Phone
(617) 714-6500
Address
325 BINNEY STREET, CAMBRIDGE
Compare MRNA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MRNA
Moderna Inc
|
33.80 | 12.09B | 3.14B | -3.36B | -4.03B | -8.73 |
|
VRTX
Vertex Pharmaceuticals Inc
|
456.20 | 113.51B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
767.96 | 78.69B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
400.23 | 52.32B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
854.99 | 52.15B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
174.84 | 35.52B | 447.02M | -1.18B | -906.14M | -6.1812 |
Moderna Inc Stock (MRNA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-12-25 | Initiated | Jefferies | Hold |
| Mar-13-25 | Initiated | Citigroup | Neutral |
| Feb-18-25 | Downgrade | Barclays | Overweight → Equal Weight |
| Jan-29-25 | Downgrade | Goldman | Buy → Neutral |
| Dec-18-24 | Downgrade | Argus | Buy → Hold |
| Dec-10-24 | Resumed | BofA Securities | Underperform |
| Nov-19-24 | Initiated | Berenberg | Hold |
| Nov-18-24 | Upgrade | HSBC Securities | Hold → Buy |
| Nov-15-24 | Initiated | Wolfe Research | Underperform |
| Oct-17-24 | Initiated | Bernstein | Mkt Perform |
| Sep-13-24 | Downgrade | JP Morgan | Neutral → Underweight |
| Sep-13-24 | Downgrade | Jefferies | Buy → Hold |
| Sep-13-24 | Downgrade | Oppenheimer | Outperform → Perform |
| Aug-28-24 | Upgrade | HSBC Securities | Reduce → Hold |
| Aug-07-24 | Upgrade | Deutsche Bank | Sell → Hold |
| Aug-05-24 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Feb-26-24 | Downgrade | HSBC Securities | Hold → Reduce |
| Jan-02-24 | Upgrade | Oppenheimer | Perform → Outperform |
| Nov-29-23 | Initiated | Canaccord Genuity | Hold |
| Nov-03-23 | Upgrade | HSBC Securities | Reduce → Hold |
| Nov-02-23 | Downgrade | Deutsche Bank | Hold → Sell |
| Aug-04-23 | Downgrade | TD Cowen | Outperform → Market Perform |
| Aug-03-23 | Downgrade | Deutsche Bank | Buy → Hold |
| Jul-24-23 | Initiated | William Blair | Mkt Perform |
| Jul-14-23 | Initiated | HSBC Securities | Reduce |
| Jun-26-23 | Upgrade | UBS | Neutral → Buy |
| Apr-26-23 | Initiated | Guggenheim | Neutral |
| Mar-13-23 | Upgrade | TD Cowen | Market Perform → Outperform |
| Mar-02-23 | Initiated | RBC Capital Mkts | Outperform |
| Feb-24-23 | Downgrade | SVB Securities | Market Perform → Underperform |
| Dec-19-22 | Upgrade | Jefferies | Hold → Buy |
| Dec-14-22 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| Oct-21-22 | Upgrade | SVB Leerink | Underperform → Mkt Perform |
| Sep-08-22 | Upgrade | Deutsche Bank | Hold → Buy |
| Feb-01-22 | Upgrade | Redburn | Sell → Neutral |
| Jan-26-22 | Upgrade | Deutsche Bank | Sell → Hold |
| Jan-21-22 | Upgrade | BofA Securities | Underperform → Neutral |
| Jan-21-22 | Initiated | UBS | Neutral |
| Dec-07-21 | Initiated | Cowen | Market Perform |
| Nov-09-21 | Initiated | Wolfe Research | Outperform |
| Oct-22-21 | Initiated | Deutsche Bank | Sell |
| Oct-15-21 | Upgrade | Piper Sandler | Neutral → Overweight |
| Aug-06-21 | Downgrade | Oppenheimer | Outperform → Perform |
| Aug-06-21 | Downgrade | Piper Sandler | Overweight → Neutral |
| Jul-15-21 | Reiterated | Jefferies | Hold |
| Feb-01-21 | Downgrade | BofA Securities | Neutral → Underperform |
| Dec-16-20 | Downgrade | Jefferies | Buy → Hold |
| Dec-16-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Dec-09-20 | Downgrade | Needham | Buy → Hold |
| Nov-23-20 | Initiated | Wells Fargo | Equal Weight |
| Nov-17-20 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Sep-08-20 | Downgrade | SVB Leerink | Mkt Perform → Underperform |
| Jul-23-20 | Initiated | SVB Leerink | Mkt Perform |
| Jul-20-20 | Downgrade | JP Morgan | Overweight → Neutral |
| Jul-13-20 | Initiated | Jefferies | Buy |
| Jun-30-20 | Initiated | Argus | Buy |
| Jun-08-20 | Initiated | Barclays | Overweight |
| Apr-30-20 | Initiated | BMO Capital Markets | Outperform |
| Mar-05-20 | Downgrade | BofA/Merrill | Buy → Neutral |
| Dec-03-19 | Resumed | BofA/Merrill | Buy |
| Oct-25-19 | Initiated | ROTH Capital | Buy |
| Apr-05-19 | Initiated | Chardan Capital Markets | Buy |
View All
Moderna Inc Stock (MRNA) Latest News
CEPI to Fund Pivotal Phase 3 Trial for Moderna's mRNA Pandemic Influenza Vaccine Candidate - Cape Cod Times
Moderna Highlights Seasonal Flu and H5 Pandemic Flu Candidates at IDWeek 2025 - Daytona Beach News-Journal
Moderna Stock (MRNA) News, Forecasts and Analysis: CEPI Bird Flu Funding, FDA Scrutiny and the 2026 Outlook (Dec. 20, 2025) - ts2.tech
Ideas Watch: How buybacks impact Moderna Inc. stock valueJuly 2025 Levels & Daily Momentum Trading Reports - Улправда
Why Is Moderna (MRNA) Stock Rocketing Higher Today - Finviz
MRNA to Get CEPI Funding for Phase III Study on Pandemic Influenza Jab - Finviz
CEPI to fund Moderna’s mRNA pandemic flu candidate - The Pharma Letter
Moderna to Present at the 44th Annual J.P. Morgan Healthcare Conference - The Marion Star
There's No Escaping Moderna, Inc.'s (NASDAQ:MRNA) Muted Revenues Despite A 28% Share Price Rise - simplywall.st
Down 80%, Should You Buy the Dip on Moderna? - AOL.com
Inside Biotech: Moderna’s bird flu funding brings pandemic preparedness back into view - Proactive financial news
Moderna gets funding for bird flu shot after HHS ends contract - The Boston Globe
Moderna gets funding for H5 pandemic influenza vaccine - BioPharma Dive
Moderna (MRNA) Valuation Check as CEPI Backs Phase 3 H5 Bird Flu Vaccine with $54.3 Million Funding - Yahoo Finance
Moderna, Inc. (MRNA): A Bull Case Theory - Finviz
Moderna, Inc. (MRNA): A bull case theory - MSN
Moderna's $54M Lifeline: Bird Flu Bet Revived After U.S. Pullbac - GuruFocus
Moderna's $54M Lifeline: Bird Flu Bet Revived After U.S. Pullback - Yahoo Finance
Why Moderna (MRNA) Stock Is Up Today - Finviz
After HHS walks away from mRNA vaccine research, Moderna finds $54M lifeline - Scripps News
Moderna gets $54.3 million investment for bird flu vaccine - upi.com
Moderna secures up to $54.3 million funding for bird flu vaccine from global coalition - Reuters
Moderna Gets Funding for Bird Flu Shot After HHS Ends Contract - Bloomberg.com
Moderna Scores $54 Million From CEPI To Fund Bird Flu Vaccine - BioSpace
Moderna (MRNA) Advances with $54.3M Boost for H5 Flu Vaccine Tri - GuruFocus
Moderna (MRNA) Secures $54.3M Funding for Bird Flu Vaccine Trial - GuruFocus
Biotech Leader Afeyan Warns That ‘Scientific Method Is Under Attack’ In The US - Citeline News & Insights
New mRNA flu shot moves to major trial in push to blunt the next pandemic - Stock Titan
Discipline and Rules-Based Execution in MRNA Response - news.stocktradersdaily.com
University of TorontoU of T and Moderna partner to advance vaccine science, cancer treatment and AI-driven therapeutics - Education News Canada
Key facts: French study confirms Moderna vaccine reduces COVID-19 deaths; Moderna to present at J.P. Morgan Healthcare Conference - TradingView — Track All Markets
Moderna (MRNA) Stock Trades Up, Here Is Why - Finviz
Moderna (NASDAQ:MRNA) Trading 5.3% HigherShould You Buy? - MarketBeat
Is Moderna Inc (MRNA) Set to Underperform? Analyzing the Factors Limiting Growth - GuruFocus
CHMP Backs EU Approval of MRNA's New COVID-19 Vaccine mNexspike - Finviz
Moderna Announces First Patient Dosed in Phase 1/2 Study of Investigational T-Cell Engager for Multiple Myeloma - Erie Times-News
Moderna (MRNA) Is Up 5.9% After EMA Backs New mNEXSPIKE VaccineHas The Bull Case Changed? - Yahoo Finance
Moderna (MRNA) swaps 4.33M employee options for 1.67M new grants - Stock Titan
EMA Committee for Medicinal Products for Human Use Adopts Positive Opinion Recommending Authorization of Moderna's mNEXSPIKE (COVID-19 Vaccine, mRNA) - Coshocton Tribune
Moderna Inc Stock (MRNA) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.44%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):